Novartis Spinoff Fights Bid To Invalidate Eye Drug Patent
A Novartis AG eye care spinoff is defending the validity of its glaucoma treatment patent in consolidated litigation brought against generic-drug makers it has accused of infringing the protection for its...To view the full article, register now.
Already a subscriber? Click here to view full article